Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
Mirati Will Use FoundationOne® Genomic Profiling Assay to Identify Patients Most Likely to Benefit from Glesatinib
View HTML
Toggle Summary Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
Mirati to Use Guardant360® Circulating Tumor DNA Diagnostic Test for Glesatinib Patient Selection and Explore the Development of Guardant360® as a Companion Diagnostic Assay
View HTML
Toggle Summary Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Study Enrolling NSCLC Patients with Genetic Alterations of the MET Gene<br>Company Announces Proposed Generic Name of "Glesatinib" for MGCD265
View HTML
Toggle Summary Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients
Study Seeks to Establish a High Response Rate Among Cancer Patients with Specific Genetic Alterations that are Drivers of Tumor Growth
View HTML
Toggle Summary Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
Completed Successful Public Offering of Common Stock that Generated $94.9 Million
View HTML
Toggle Summary Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors
Data Presented at the 2015 European Cancer Congress Demonstrates MGCD516 is Well Tolerated with Favorable PK Profile
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering of $80 Million of Common Stock View HTML
Toggle Summary Mirati Therapeutics To Present Clinical Data At The European Society for Medical Oncology (ESMO) 2015 European Cancer Congress
Company to Present Data from Phase 1/1b Study of MGCD516
View HTML